Yalin Tu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yalin Tu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Alfred Sze Lok Cheng
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China
18 shared publications - Anthony Wing Hung Chan
Department of Anatomical and Cellular Pathology, State Key Laboratory in Oncology in South China Prince of Wales Hospital, The Chinese University of Hong Kong Shatin Hong Kong
17 shared publications - Jingying Zhou
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR 999077, China
17 shared publications - Ka-Fai To
Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China
17 shared publications - Weiqin Yang
School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China
17 shared publications - Dan Michelle Wang
School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
16 shared publications
Latest Publications
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors